Larsson K
Eur J Respir Dis Suppl. 1985;141:1-52.
The aims of the present studies were to investigate sympatho-adrenal mechanisms and adrenergic receptor function in patients with bronchial asthma and healthy subjects. The patients were characterized with regard to the occurrence of exercise-, histamine- or allergen-induced bronchoconstriction in pre-trial tests. All medication was withdrawn during at least one week prior to the trials, in order to eliminate the influence of treatment. The patients were asymptomatic and had basal PEFR greater than 70% of predicted values prior to the trials. Healthy control subjects were matched with regard to sex and age. Alpha- and beta-adrenoceptor responsiveness were studied with improved in vivo-techniques, where different responses were related to plasma concentrations rather than doses of the agonists administered. Sympatho-adrenal reactivity, as assessed by plasma noradrenaline and adrenaline responses, to an orthostatic test and exercise was normal in asthmatic subjects. Surprisingly, there was no plasma catecholamines response to histamine- or allergen-induced bronchoconstriction. High plasma levels of noradrenaline and phenylephrine (by i.v. infusion) had little or no influence on bronchial tone, despite marked cardiovascular effects, in patients with exercise-induced asthma (EIA) or healthy subjects. Elevation of circulating noradrenaline failed to alter bronchial hyperreactivity to histamine in asthmatic patients. The blood pressure responses to infused noradrenaline and phenylephrine were similar in patients with EIA and healthy subjects, but the ensuing bradycardia was more pronounced in the EIA-patients indicating an increased baroreceptor sensitivity in these patients. High, but physiological, plasma levels of adrenaline dilated the airways with regard to end-expiratory flow rates but not Sgaw or PEFR. Furthermore, allergen-induced bronchoconstriction was counteracted by elevation of circulating adrenaline in patients with allergic asthma. These findings indicate that adrenaline may participate in the regulation of airway tone under physiological conditions. Beta 2-adrenoceptor sensitivity was found to be reduced in patients with EIA when assessed by both in vitro and in vivo techniques, while patients with non-exercise induced asthma did not differ from controls in this respect. Lymphocytes from EIA-patients had a reduced cAMP response to isoprenaline. Furthermore, the beta 2-mediated increase in plasma cAMP and the reduction of diastolic blood pressure in response to i.v. isoprenaline infusions were attenuated in the EIA-patients. These results do not seem to be influenced by previous anti-asthmatic drug treatment or the severity of the disease.(ABSTRACT TRUNCATED AT 400 WORDS)
本研究的目的是调查支气管哮喘患者和健康受试者的交感 - 肾上腺机制及肾上腺素能受体功能。在试验前的测试中,根据运动、组胺或过敏原诱发支气管收缩的情况对患者进行特征描述。在试验前至少一周停用所有药物,以消除治疗的影响。试验前患者无症状,基础呼气峰流速(PEFR)大于预测值的70%。健康对照受试者在性别和年龄方面进行了匹配。采用改进的体内技术研究α和β肾上腺素能受体反应性,其中不同反应与血浆浓度而非所给予激动剂的剂量相关。通过血浆去甲肾上腺素和肾上腺素反应评估的交感 - 肾上腺反应性,在哮喘患者中,对直立试验和运动的反应正常。令人惊讶的是,组胺或过敏原诱发支气管收缩时,血浆儿茶酚胺无反应。在运动诱发哮喘(EIA)患者或健康受试者中,尽管有明显的心血管效应,但静脉输注去甲肾上腺素和苯肾上腺素使血浆水平升高对支气管张力几乎没有影响。哮喘患者循环去甲肾上腺素升高未能改变对组胺的支气管高反应性。EIA患者和健康受试者对输注去甲肾上腺素和苯肾上腺素的血压反应相似,但随后的心动过缓在EIA患者中更明显,表明这些患者的压力感受器敏感性增加。高但仍处于生理水平的血浆肾上腺素浓度可使呼气末流速时气道扩张,但对比气道传导率(Sgaw)或PEFR无影响。此外,在过敏性哮喘患者中,循环肾上腺素升高可对抗过敏原诱发的支气管收缩。这些发现表明,在生理条件下肾上腺素可能参与气道张力的调节。通过体外和体内技术评估发现,EIA患者的β2肾上腺素能受体敏感性降低,而非运动诱发哮喘患者在这方面与对照组无差异。EIA患者的淋巴细胞对异丙肾上腺素的环磷酸腺苷(cAMP)反应降低。此外,EIA患者静脉输注异丙肾上腺素后,β2介导的血浆cAMP升高和舒张压降低减弱。这些结果似乎不受先前抗哮喘药物治疗或疾病严重程度的影响。(摘要截断于400字)